



# ANNUAL MEETING

19<sup>th</sup>- 21<sup>st</sup> January 2018

WEIZMANN INSTITUTE OF SCIENCE, REHOVOT, ISRAEL

## DAY 1 FRIDAY 19<sup>th</sup> JANUARY

Arrival of AtheroFlux guests in Rehovot, Israel

18.30-19.00 **General Assembly**

19.00 *Networking dinner*

## DAY 2 SATURDAY 20<sup>th</sup> JANUARY

09.30-09.45 **Coordinator address**  
Marc Feldmann - University of Oxford, United Kingdom

09.45-10.45 **WP 1 Discovery of key regulatory nodes within SL biosynthesis in patients with coronary artery diseases via Flux methodologies**  
Reijo Laaksonen (WP leader) - Zora Biosciences OY, Finland (20 mins)  
Discussion (40 mins)

10.45-11.15 *Coffee break*

11.15-12.15 **WP5 Development of LNA oligonucleotide-based therapeutics targeting SL metabolism and its associated signalling**  
Steffen Schmidt (WP leader) - Roche Innovation Center Copenhagen, Denmark (20 mins)  
Discussion (40 mins)

12.15-14.00 *Lunch*

14.00-14.45 **AtheroFlux Mini-symposium**  
Young Researcher presentations (10 mins plus 5 mins questions)  
14.00-14.15 Natacha Zanin - University of Oxford, United Kingdom  
14.15-14.30 João Ricardo Diniz de Araújo - Institut Pasteur, France  
14.30-14.45 Leena Eloni - Tampere University Hospital, Finland

14.45-15.30 *Coffee break*

15.30-16.15 **WP2 Genome-scale RNAi screening to reveal rate-limiting pathways in ceramide metabolism and signalling**  
Michael Hannus (WP leader) - siTOOLS Biotech GmbH, Germany (10 mins)  
Ejsing Christer - Syddansk Universitet, Denmark (10 mins)  
Discussion (25 mins)

16.15-17.00 **WP3 Evaluation of the significance of prospective therapeutic targets within the SL pathway in terms of inflammatory signalling**  
Zhong-Qun Yan (WP leader) - Karolinska Institutet, Sweden (10 mins)  
Tony Futerman - Weizmann Institute of Science, Israel (10 mins)  
Discussion (25 mins)

19.00 *Networking dinner*



# ANNUAL MEETING

19<sup>th</sup>- 21<sup>st</sup> January 2018

WEIZMANN INSTITUTE OF SCIENCE, REHOVOT, ISRAEL

## DAY 3

## SUNDAY 21<sup>st</sup> JANUARY

09.00-09.45

### **WP4 Evaluation of biodistribution, bioactivity and pro-atherogenic properties of alterations in SL metabolism**

Evangelos Andreakos (WP leader) - Biomedical Research Foundation Academy of Athens, Greece (20 mins)

Discussion (25 mins)

09.45-10.15

### **WP6 Management, Review and Assessment**

### **WP7 Dissemination and Diffusion of project results**

Paola Cesaroni - ALTA Ricerca e Sviluppo in Biotecnologie (30 mins)

10.15-10.45

*Coffee break*

10.45-12.45

### **AtheroFlux Steering Committee**

12.45

Departures